Consensus MaaT Pharma

Equities

MAAT

FR0012634822

Market Closed - Euronext Paris Other stock markets 08:05:14 2024-04-26 EDT			5-day change	1st Jan Change
9.06 ^EUR	0.00%		+3.90%	+29.80%

04-15	MaaT Pharma: positive data in graft-versus-host disease	CF
04-15	MaaT Pharma Presents Positive 18-Month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access Program at the 2024 EBMT Event	CI

Evolution of the average Target Price on MaaT Pharma

Price target over the last 5 years

History of analyst recommendation changes

2aeb37706ec933db61812.1EbQH3mtokMYBlm-T48QhUYqUGwsV5vGtUeAVpkr8I4.pymyWhLu1nFObTPtKusj0C9FFQ1jHOue4n7KE9RExNyeIZxZFuTWcEBHFA~e3b2a6fe7d8e2e17b7809ac0ca1b5a54

Analyst Recommendations on MaaT Pharma

Fragmented feeling?	11-06
But where have the bears gone?	11-03
MaaT Pharma's Immune Disorder Therapy Shows Improved Survival Rate In Clinical Trials	21-12-13	MT